<DOC>
	<DOCNO>NCT00757419</DOCNO>
	<brief_summary>The aim establish maximal tolerate dose AZD3355 selection dose up-coming study . This do comparing single repeat dos AZD3355 placebo ( `` inactive substance '' ) . Safety tolerability variable closely monitor throughout study .</brief_summary>
	<brief_title>AZD3355 Dose-escalation Study Healthy Males</brief_title>
	<detailed_description />
	<mesh_term>Lesogaberan</mesh_term>
	<criteria>Subjects without concurrent disease require medical treatment Provision sign informed consent . History somatic disease/condition , may interfere objective study , judge investigator . Clinically significant illness clinically relevant trauma within 2 week prior administration investigational product , judged investigator . History clinically significant orthostatic reaction syncope Clinically important abnormality relate heart function</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>healthy subject</keyword>
</DOC>